Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-005 in healthy volunteers
NCT06294301Phase 1Completed
- Sponsor
- LongBio Pharma
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised trial of LP-005 in paroxysmal nocturnal hemoglobinuria (PNH) (11 cohorts), sponsored by LongBio Pharma. Primary endpoint: Adverse Events at 78 days. Started Nov 2023; status: completed.
02
Drugs
LP-005
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06294301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06294301.